TimesSquare Capital Management LLC Makes New Investment in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

TimesSquare Capital Management LLC bought a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 504,340 shares of the company's stock, valued at approximately $12,533,000. TimesSquare Capital Management LLC owned about 1.47% of RAPT Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of RAPT Therapeutics by 347.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,981 shares of the company's stock worth $99,000 after buying an additional 3,092 shares during the period. Exchange Traded Concepts LLC boosted its holdings in RAPT Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 7,190 shares of the company's stock valued at $179,000 after acquiring an additional 1,824 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at about $233,000. SG Americas Securities LLC bought a new position in shares of RAPT Therapeutics in the fourth quarter worth about $244,000. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of RAPT Therapeutics by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 40,565 shares of the company's stock worth $674,000 after purchasing an additional 19,161 shares during the last quarter. 99.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on RAPT shares. Cantor Fitzgerald downgraded RAPT Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, February 20th. Leerink Partnrs downgraded shares of RAPT Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 21st. UBS Group lowered shares of RAPT Therapeutics from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $61.00 to $10.00 in a research report on Thursday, February 22nd. Guggenheim cut shares of RAPT Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday. Finally, Evercore ISI assumed coverage on RAPT Therapeutics in a research report on Friday, February 16th. They set an "outperform" rating on the stock. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $24.67.

RAPT Therapeutics Stock Performance

Shares of RAPT stock traded down $0.33 during trading hours on Friday, hitting $4.33. The company had a trading volume of 2,152,592 shares, compared to its average volume of 1,156,101. The firm has a market capitalization of $150.68 million, a price-to-earnings ratio of -1.48 and a beta of 0.52. RAPT Therapeutics, Inc. has a 12 month low of $4.18 and a 12 month high of $27.35. The firm's fifty day moving average is $8.32 and its 200 day moving average is $15.19.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.05. On average, sell-side analysts expect that RAPT Therapeutics, Inc. will post -3.19 EPS for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.